I always assumed the Genentech deal was targeting pseudomonas aeruginosa but then again the obvious assumption has been wrong before.
Phylogica have always had good (in the company's own words) hits against PA and earlier deals have been based on targeting PA. Roche / Genentech have signed 3 or 4 deals against PA over the last 2-3 years so they obviously have a strong interest there > Polyphor $500M ? & Discuva were the first stitched two by Roche on re-entering the antimicrobial space & pretty sure there has been another one from Genentech targeting PA and maybe another from Roche ?
PYC Price at posting:
1.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)